Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > VOLUNTARY ANNOUNCEMENT - MARKETING AUTHORISATION APPLICATION FOR PERTUZUMAB INJECTION ACCEPTED BY THE NMPA

VOLUNTARY ANNOUNCEMENT - MARKETING AUTHORISATION APPLICATION FOR PERTUZUMAB INJECTION ACCEPTED BY THE NMPA

November 12, 2025

a251112_00.jpg

Previous: VOLUNTARY ANNOUNCEMENT - A SELECTIVE 5-HT2A RECEPTOR AGONIST (SYH2056 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

Next: VOLUNTARY ANNOUNCEMENT - SYH2061 INJECTION (A DOUBLE-STRANDED SMALL INTERFERING RNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC PHARMACEUTICAL GROUP LIMITED All Rights Reserved | 冀ICP备05003393号

Wechat